Validation of the new IDF-DAR risk assessment tool for Ramadan fasting in patients with diabetes in a primary healthcare setting.

Author:

Alketbi Latifa Baynouna1,Afandi Bachar2,Nagelkerke Nico3,Abdubaqi Hanan1,Nuaimi Ruqaya Al1,Saedi Mariam Al1,Blooshi Fatima Al1,Blooshi Noura Al1,AlAryani Aysha1,AlMarzooqi Nouf1,Khouri Amal Al1,Mansoori Shamsa Al1,Hassanein Mohammad4

Affiliation:

1. Ambulatory Healthcare Services. Abu Dhabi Healthcare Services

2. Tawam Hospital

3. United Arab Emirates University

4. Dubai University

Abstract

Abstract Background: In diabetic patients intending to fast, Ramadan, risk assessment, and stratification are essential for an individualized treatment plan. The new IDF-DAR risk stratification tool (International Diabetes Federation - Diabetes and Ramadan Alliance) is becoming the primary tool. This study aims to validate this tool in the Abu Dhabi population. Method IDF-DAR risk stratification assessment was done before Ramadan, followed by assessing any significant outcome after Ramadan. Patients were included if the attending physicians used the tool in the risk assessment of the patients within six weeks before Ramadan 1444, 2022, in the AHS healthcare center. After Ramadan, assessment was done through tele-interview and Electronic Medical Records review. Results Patients included in the study were 435, excluding 21 patients with type 1 Diabetes. Half of the patients were in the low-risk category of the IDF-DAR risk stratification tool (51.7%), 28.5% in the moderate-risk category, and 19.8% in the higher-risk category. Most of those patients fasted all of Ramadan, 81.3%, and the remaining 28.7% attempted to fast but had to break their fast; among them, only 17 (3.9%)did not fast for 15 days or more. The lower-risk group was younger, with an average age of 56.3 years, compared to the moderate and high-risk risk, who had an average age of 59 and 64.5 years, respectively. Diabetes control was progressively worse with increasing the DAR risk category with an average HbA1C of 7.18, 8.2, and 9 for the low, moderate, and high-risk categories. From all the sample, 14 (3.8%) were admitted at least once, and 56 (12.9%) had at least one significant event, including admission to the hospital. Using logistic regression, the determinant factor of not having an adverse event was fasting more days, B=-0.08 OR=0.92 (0.86-0.99) p value=0.023. Another independent risk factor was being in the low-risk category of the DAR risk assessment tool B=-1.2, OR= 0.29 (0.09-0.95)p value=0.042 and having a higher frailty score was the third independent risk factor, B=0.4, OR=1.5 (1-2.02-1.86) p value=0.039. Conclusion Diabetic patients in the Low-risk category, according to the IDF-DAR risk assessment, had a better outcome than the Moderate or high-risk categories during Ramadan regarding significant adverse events. Another independent risk factor is if the patient is Frail, according to the FRAIL scoring.

Publisher

Research Square Platform LLC

Reference12 articles.

1. A systematic review on the safety of Ramadan fasting in high-risk patients with Diabetes;Rashid F;Diabetes Res Clin Pract,2020

2. IDF, Diabetes, Ramadan IDF-DAR, Practical Guidelines. 2021. 2021. Available from: https://www.daralliance.org/daralliance/idf-dar-practical-guidelines-2021/.

3. Validation of the new IDF-DAR risk assessment tool for Ramadan fasting in patients with diabetes;Mohammed N;Diabetes Metab Syndr,2023

4. Evidence-based risk factors for major complications during Ramadan fasting in people with diabetes grouped under IDF-DAR risk categories;Rahmatullah, Ahmedani MY;Diabetes Res Clin Pract,2022

5. Risk stratification using the 2021 IDF-DAR risk calculator and fasting experience of Bangladeshi subjects with type 2 diabetes in Ramadan: The DAR-BAN study;Kamrul-Hasan ABM;J Clin Transl Endocrinol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3